Indication
Myeloproliferative Disorders
14 clinical trials
20 products
4 drugs
Product
EPZ-5676Clinical trial
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic MalignanciesStatus: Completed, Estimated PCD: 2015-11-01
Clinical trial
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis and Essential Thrombocytopenia)Status: Active (not recruiting), Estimated PCD: 2024-10-31
Product
RuxolitinibProduct
PelabresibProduct
ThrombosomesProduct
Liquid Stored PlateletsClinical trial
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic PatientsStatus: Terminated, Estimated PCD: 2022-01-07
Clinical trial
Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Reduced Intensity Allogeneic Stem Cell TransplantStatus: Not yet recruiting, Estimated PCD: 2028-02-01
Product
ATGClinical trial
Evaluation of Ruxolitinib and Lenalidomide Combination as a Therapy for Patients With MyelofibrosisStatus: Completed, Estimated PCD: 2018-09-05
Product
LenalidomideProduct
PrednisoneClinical trial
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell TransfusionsStatus: Recruiting, Estimated PCD: 2025-03-27
Product
ACE-536Clinical trial
Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients With Debilitating Hematologic DiseasesStatus: Completed, Estimated PCD: 2018-12-14
Product
MethotrexateProduct
CyclosporineDrug
FilgrastimClinical trial
Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Myeloablative Allogeneic Stem Cell TransplantStatus: Not yet recruiting, Estimated PCD: 2025-10-29
Clinical trial
Phase 1a/1b Study of Itacitinib (INCB039110) for Cytokine Release Syndrome Prevention and Minimization of Immunosuppression Following Nonmyeloablative Related Partially HLA-mismatched Peripheral Blood Stem Cell Transplant (PBSCT) With High-dose Posttransplantation Cyclophosphamide in Older Patients (Age 60 Years)Status: Recruiting, Estimated PCD: 2028-03-01
Product
ItacitinibClinical trial
PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell TransplantStatus: Terminated, Estimated PCD: 2020-08-17
Clinical trial
PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)Status: Completed, Estimated PCD: 2023-05-26
Product
IFN-alpha2aClinical trial
Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell TransplantationStatus: Completed, Estimated PCD: 2022-08-11
Product
FludarabineProduct
BusulfanDrug
VarlilumabDrug
DocetaxelClinical trial
Cytokine-induced Memory-like Natural Killer Cell Therapy After Hematopoietic Stem Cell Transplantation for Eradication of Measurable Residual Disease, a Phase I/Ib Clinical TrialStatus: Recruiting, Estimated PCD: 2026-02-28
Drug
interleukin-2Clinical trial
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative NeoplasmsStatus: Recruiting, Estimated PCD: 2025-10-01
Product
JNJ-88549968